newsfilter
← Latest News
GlobeNewswire·

Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

Enables expansion of ongoing vitiligo clinical study to U.S. investigational sitesTopline data anticipated Q4 2027 TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage